Clinical trialNCT04665206RecruitingPhase 1/PHASE2Interventional

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

SponsorVivace Therapeutics, IncEnrollment434MesotheliomaNSCLCSolid Tumor, Adult

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Neelesh Sharma, MD
Vivace Therapeutics
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Monash Health
Clayton, Victoria, Australia
Recruiting
Peter Maccullum Cancer Centre
Melbourne, Victoria, Australia
Recruiting
Linear Clinical Research
Nedlands, Western Australia, Australia
Recruiting

United States

Ucsf Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Recruiting
University of Chicago Medical Center
Chicago, Illinois, United States
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Recruiting
M Health Fairview University of Minnesota Medical Center
Minneapolis, Minnesota, United States
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Recruiting
Next Oncology
San Antonio, Texas, United States
Recruiting
Virginia Cancer Specialists, Pc
Arlington, Virginia, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Nivolumab & IpilimumabOsimertinib →Pemetrexed →VT3989

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Mar 2021
Primary completion: 2 Nov 2029
Completion: 2 Mar 2030
Last update posted: 2 Apr 2026
Registered enrollment: 434
Registry id: NCT04665206

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.